Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E. Other stock markets 16/01/2026			5-day change	1st Jan Change
209,000.00 ^KRW	-0.71%		-3.69%	+15.47%

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT

Transcript : Celltrion, Inc. - Analyst/Investor Day

Published on 11/27/2024 at 07:00 am GMT

S&P Capital IQ

Presenter Speech
Unknown Executive (Executives)

Good afternoon, everyone. Thank you for joining us today. My name is [indiscernible], Head of the Global IR at Celltrion. And this is our first in time

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Celltrion, Inc.

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
01-02	Health Care Up on Anti-Obesity Drug Sales Outlook - Health Care Roundup	DJ
01-02	Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).	CI
01-02	Celltrion Shares Rally on U.S. Contract, Earnings Outlook	DJ
01-01	Celltrion Inc U.S. unit Celltrion USA signs production contract with Eli Lilly worth 473 million USD	RE
12-21	Samsung Biologics to buy US drug production facility from GSK for $280 million	RE
12-18	Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector	CI
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
12-11	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI
12-10	Celltrion, Inc. announces Annual dividend	CI
12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI
11-26	Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)	CI
11-19	Celltrion to invest up to $478 million to expand US factory in response to tariffs	RE
11-18	Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg	CI
11-18	Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab	CI
11-14	Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Prime Medicine Q3 net loss narrows	RE
30/10/25	U.S. FDA Grants Interchangeability Designations to Celltrion's Denosumab Biosimilar, STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo)	CI
22/10/25	Celltrion to sell 746 million won worth of own shares	RE
21/10/25	Celltrion's Q3 Operating Income, Sales Rise	MT
20/10/25	Wellscare Signs A Memorandum of Understanding with Celltrion Canada	CI
17/10/25	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on September 17, 2025.	CI